The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features

• Автори: Hélène Salaün (Автор), Lounes Djerroudi (Автор), Laura Haik (Автор), Anne Schnitzler (Автор), Guillaume Bataillon (Автор), Gabrielle Deniziaut (Автор), Ivan Bièche (Автор), Anne Vincent‐Salomon (Автор), Marc Debled (Автор), Paul Cottu (Автор)
• Формат: Книга
• Опубліковано: Wiley, 2024-05-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Abstract Everolimus is widely used in patients with advanced ER‐positive, HER2‐negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER‐positive, HER2‐negative breast cancer treated with eve...